Novartis reports favourable data from Phase III extension trial of Cosentyx for AS

Novartis has reported positive results from the Phase III MEASURE 1 extension trial of Cosentyx (secukinumab) to treat patients with active ankylosing spondylitis (AS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news